Highland Funds I – Highland Opportunities and Income Fund (NYSE:HFRO) to Issue Monthly Dividend of $0.04
by Amy Steele · The Cerbat GemHighland Funds I – Highland Opportunities and Income Fund (NYSE:HFRO – Get Free Report) announced a monthly dividend on Thursday, October 1st. Investors of record on Friday, October 23rd will be paid a dividend of $0.0385 per share on Friday, October 30th. This represents a $0.46 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, October 23rd.
Highland Funds I – Highland Opportunities and Income Fund Price Performance
Shares of HFRO opened at $6.72 on Friday. The stock has a 50-day moving average price of $7.19 and a 200 day moving average price of $6.76. Highland Funds I – Highland Opportunities and Income Fund has a one year low of $5.47 and a one year high of $7.74.
Highland Funds I – Highland Opportunities and Income Fund declared that its Board of Directors has initiated a stock buyback program on Tuesday, June 9th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
Highland Funds I – Highland Opportunities and Income Fund Company Profile
Highland Funds I – Highland Opportunities and Income Fund is a closed-end investment fund listed on the New York Stock Exchange under the symbol HFRO. Rather than operating a commercial business, the fund seeks to provide investors with current income and the potential for capital appreciation through a managed portfolio of investments.
The fund invests in a range of debt and equity securities, including corporate credit, structured investments and other income-producing or opportunistic assets.
Featured Articles
- Five stocks we like better than Highland Funds I – Highland Opportunities and Income Fund
- Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
- Why Concentra’s Quiet Healthcare Business Keeps Winning
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight